Home • SuperSonic Imagine • Supervisory Board

Supervisory Board


Hans Barella

Hans Barella, President of the Supervisory Board of SuperSonic Imagine, was previously President and Chief Executive Officer of Philips Medical Systems and member of the Group Management Committee of Royal Philips Electronics.

Hans Barella has, for the past 30 years, occupied several key positions at Philips Medical Systems, including commercial, marketing and technical roles. He became member of the top management team in 1985 and was appointed President and CEO of Philips Medical Systems in 1997. In this role, he initiated an ambitious acquisition program and consolidated five major companies into one organization dedicated to diagnostics, treatment and patient monitoring.

Additionally, from 1992 to 1996, he was Chairman of COCIR: the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry.

Hans Barella has been a member of the Board of Directors of Elekta AB, Sweden since 2003.

Mr. Barella has a Masters of Business Administration (MBA) and an Electronic Engineering degree.



Philippe Boucheron

Philippe Boucheron is the co-founder Bioam Funds. He sits on the board of several Biotech of Medtech companies.

Between 1993 and 1996, Philippe Boucheron worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare.
From 1997 to 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris. Here, he spent a significant part of his time following French and European listed biotech companies. In 2000, he co-founded the Bioam Funds dedicated to early-stage life science investments and became Investment Manager, then in 2004 Managing Partner.
After the merger of Bioam with CDC entreprises in July 2010, Philippe Boucheron joined the CDC Entreprises life sciences' team as Investment Manager.
In 2013, CDC Entreprises, FSI and Oséo merged to create Bpifrance. Since then, he is deputy chief of the Life Investments BU and sits on Bpifrance Investissement's Investment Committee. Philippe Boucheron also sits on the boards of Ademtech, Integragen, SSI, Advicenne, ART, GamaMabs and CorWave. Philippe Boucheron holds an engineering degree in Biochemical Engineering and Microbial genetics from the Institut National des Sciences Appliquées in Toulouse, a MSc in Biochemical Engineering from the Ecole Polytechnique.



Aris Constantinides

Aris Constantinides is the founder and Investment Director of London-based NBGI Ventures, one of the few European venture capital firms investing exclusively in medical technology companies. Aris currently serves on the boards of a number of medtech companies including: 2010 Perfect Vision, Endoscopic Technologies, EOS Imaging, Forth Photonics Limited, Reverse Medical and SuperSonic Imagine.

Aris started his career at Bankers Trust where he was a structurer of innovative derivative products.  He has more than 14 years of experience with European venture capital and private equity, including Deutsche Bank’s and Credit Suisse First Boston’s funds.  
He holds Mechanical Engineering degrees from Imperial College and MIT an MBA from Insead.



Bernard Daugeras

Co-founder Chairman of the Board of Auriga Partners, Bernard is an expert in Life Sciences and was behind successful investments such as BioAlliance Pharma (EuroNext : BIO), NicOx (EuroNext : COX). He is a member of the French Academy of Technologies.

Bernard began his career doing research into particle physics at the University of Orsay, the University of California at Berkeley, and CNRS, the French national scientific research center. He subsequently held senior posts at the French Ministry of Industry and Research, where he was in charge of promoting technology transfer from research institutions and of optimizing relations between Research and Industry. After 4 years in the Crédit Lyonnais setting up the bank's Venture Capital arm, he joined Finovelec in 1990. Bernard is a graduate of the Ecole Polytechnique and has a PhD from the University of Orsay.



Olivier Litzka

Olivier Litzka joined Edmond de Rothschild Investment Partners’ (EdRIP) as a partner in 2006. He invests in Biotechnology and Medtech companies mainly in Europe, but also selectively in the US.

Olivier serves on the boards of Noxxon Pharma (Berlin), Endosense (Geneva), JenaValve (Munich), and Probiodrug (Halle), as well as SuperSonic Imagine.  Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France).

Before joining EdRIP, Olivier spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting, both in Munich and Paris.

Olivier holds a PhD in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and performed his scientific research work over several years in Munich and Oxford.


Sabine Lochmann

Sabine Lochmann

Managing Director, BPI Group.
Sabine Lochmann has a dual French-American legal background. She is a graduate of Paris 1 Panthéon-Sorbonne and the University of Davis, California (LLB in business law). Additionally, Sabine completed an Executive Leadership Program in South Africa (University of Cape Town).
Sabine began her career as a lawyer focused in the services sector, working with Jacobs Serete and JC Decaux before taking direction of the legal department of Johnson & Johnson France in 1998.  
In 2008, she accepted a new career challenge in, assuming the role of Marketing Director at Johnson & Johnson, followed by General Director in charge of Market Access, and then General Director of government and strategic affairs in 2010.
She is also actively involved in a number of professional organizations, including “Juristes d’Entreprise” (AFJE), of which she served as President from 2001 to 2005. She also served as Vice President of the European Confederation of business lawyers (ECLA) from 2003 to 2006.
Sabine has also founded several think-tanks, including “Avenir Femmes Santé” in 2011, dedicated to women’s health issues, and the “Ateliers de la Convergence” in January 2012, bringing together business leaders, social partners, and HR specialists on the subject of competitiveness, employment, and legal issues. Since April 2013, she had joined Supersonic Imagine as Independent board Director.

Sabine joined BPI group as Managing Director in 2014, and focuses on commercial development in France and internationally.


Alexia Perouse

Alexia Perouse has a mix Neurosciences & Management of Enterprise background and joined the venture capital field in 1999. Partner at Omnes Capital, she invests in Life science and  has developed the Medical Device portfolio.

Alexia Perouse has particularly followed the companies Biolipox (merged with Orexo in 2007) and Mutabilis (sold to Pharma Omnium International in 2009).
She has invested in Fovea Pharmaceuticals (sold to Sanofi Aventis in 2009). In addition of her investment in SuperSonic Imagine since the Serie A, she has developed the Medtech portfolio through numerous investments in Cellnovo, CircuLite, Eos Imaging, EyeTechCare, SpineGuard and Stentys (IPO in 2010). She currently sits at 6 boards.

Before joining the venture capital within Sofinnova Partners and then  CAPE in 2005, Alexia Perouse has carried out missions of consulting & business development at Parteurop Développement for biotech start-ups. She started her career as an analyst at Chiron Vaccines.



François Valencony

Francois Valencony started his work experience within Schneider Electric in the USA, supporting several acquisitions and growth projects for the North American division until 2000. He then actively participated in the build-up of a start-up IT company out of London in 2000, subsequently acquired by Descartes group.

François has been working for Institut Merieux since 2003, leading several transactions for the group, including an exclusive license agreement between Roche and Transgene in 2007 and a structured option with Novartis on a Phase IIB drug candidate. Operational responsibilities included the set-up of the first research center of bioMerieux in China, focusing on emerging pathogens and the project management of 5 vaccine programs in the field of infectious diseases and oncology. Francois is currently General Manager of Merieux Développement, the private equity arm of Institut Merieux focusing on healthcare investments. François graduated from HEC in Paris and holds a Master Degree from CEMS out of Köln, Germany.